Cortagen

What is Cortagen?

Cortagen is a synthetic peptide bioregulator developed to target brain cortex tissue. Part of the Khavinson peptide bioregulator family, it is designed to normalize gene expression in cortical neurons, potentially supporting cognitive function, memory, and neuroprotection, particularly in aging populations.

What Cortagen Is Investigated For

Cortagen is a Khavinson-program tetrapeptide (Ala-Glu-Asp-Pro) investigated for cognitive function in aging, memory enhancement, and neuroprotection, positioned as the synthesized short-peptide counterpart of the older natural-extract preparation Cortexin. The published preclinical evidence base is modest — a small set of Khavinson-group studies on sciatic nerve regeneration, gene expression in mouse heart via microarray, and brain function in chronic ischemia models — and no PubMed-indexed Western RCTs exist for Cortagen as a cognitive-enhancement or neuroprotection therapy. The strongest available clinical signal comes indirectly from broader Cortexin literature in Russian neurology plus general Khavinson-program claims about short-peptide gene regulation, which is not the same as direct Cortagen efficacy data. Independent Western preclinical replication is essentially absent, the direct-DNA-interaction mechanism proposed by the originating group remains contested, and Cortagen is frequently conflated with the related but distinct Cortexin preparation. It is not FDA-approved, not on the 503A compounding list, and cognitive-enhancement claims in healthy adults significantly exceed what the peptide-specific evidence supports.

History & Discovery

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed by Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. It is the synthesized short-peptide counterpart of Cortexin, an older natural-extract preparation derived from cattle cerebral cortex tissue that the Khavinson group and Russian clinicians had used since the 1980s. The strategy mirrors other Khavinson bioregulator pairs: identify a putative active motif from the larger tissue extract, synthesize it as a chemically defined short peptide, and pursue tissue-specific gene-regulatory claims for the synthesized form. The derivation is documented rather than merely asserted: the 2004 microarray paper states that Cortagen 'was obtained by directed synthesis based on amino acid analysis of natural brain cortex peptide preparation Cortexin' (PMID 15159690). The tissue-targeting claim traces to a single 2001 experiment in which Cortagen, Epithalon, Livagen and Vilon each stimulated growth of organotypic explants from the tissue their parent extract came from — cortex, pineal, liver and thymus respectively (PMID 11713572). The published preclinical record for Cortagen specifically is modest — sixteen PubMed-indexed records in total across twenty-five years, reporting effects on sciatic nerve regeneration, gene expression in mouse heart by microarray, hypothalamic IL-2 transcription, free-radical processes in rat cerebral cortex, and brain function in chronic ischemia models. Independent Western preclinical replication is essentially absent, and no PubMed-indexed Western RCTs exist for Cortagen as a cognitive-enhancement or neuroprotection therapy. The cognitive claims circulating in Western longevity and nootropic communities lean heavily on the broader Cortexin clinical experience plus extrapolation from the Khavinson program's general claims about short-peptide gene regulation, rather than on specific high-quality Cortagen efficacy data.

How It Works

The idea behind Cortagen is that a four-amino-acid peptide small enough to reach a cell nucleus can switch cortical genes back on as they fade with age. That is the proposal, not a finding — most of what has actually been measured for Cortagen was measured in other tissues, and no published experiment has tested whether it improves memory or learning in an animal.

The Khavinson program proposes that Cortagen enters cortical neurons and interacts directly with DNA regulatory regions, modulating genes for neuronal survival, synaptic plasticity, and neurotransmitter synthesis. It is worth separating that proposal from the Cortagen-specific measurements that exist, because they do not line up neatly. What has been measured in nervous tissue. Cortagen stimulated growth of organotypic explants of rat brain cortex, the result the tissue-specificity claim rests on (PMID 11713572). Injected into rats, it modulated IL-2 gene expression in hypothalamic structures in vivo — the only indexed demonstration of Cortagen altering gene expression inside a living brain, and the gene is an immune signal rather than a synaptic one (PMID 16224591). In rats it reduced lipid-peroxidation products and oxidative protein modification in serum and cerebral cortex (PMID 18239817), and in chronic cerebral ischemia models it partially restored behaviour disrupted by the lesion and acted as an antioxidant (PMIDs 21476278, 26902350). Earlier work found accelerated sciatic-nerve regeneration, with conduction velocity up about 40% (PMID 11276314). What has been measured elsewhere. The chromatin-remodeling evidence often quoted as a brain mechanism comes from human peripheral lymphocytes, not neurons (PMID 15085253). The widest gene-expression dataset for Cortagen is a microarray of 15,247 transcripts in mouse heart (PMID 15159690). Immune readouts in splenocytes and thymocytes place it at the weak end of the Khavinson series — in splenocytes Vilon and Epithalon were most potent while Cortagen produced a less pronounced effect on IL-2 mRNA (PMID 12447482), and in thymocytes it produced no comitogenic or sphingomyelinase effect at all (PMID 12420072). So the honest summary is that Cortagen demonstrably does something to cortical explants and to ischemic rat brains, and that the synaptic-plasticity and neurotransmitter-synthesis parts of the proposed mechanism have never been measured for this peptide in any published experiment.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Cortagen:

• 01Independent replication outside the Khavinson research program — preclinical and clinical findings have not been reproduced by Western laboratories under modern trial-methodology standards.
• 02Blinded randomized controlled trials in humans for cognitive enhancement, memory, neuroprotection, or any clinical endpoint specific to Cortagen.
• 03Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of the intact tetrapeptide), blood-brain-barrier penetration, distribution, and clearance have not been characterized.
• 04Mechanism specificity — the proposed mechanism of direct DNA interaction by a tetrapeptide and the resulting cortex-specific gene reactivation claim has not been independently validated.
• 05Long-term safety with cumulative repeated courses, including any effects on neurogenesis-related malignancy risk.
• 06Distinction from Cortexin — the natural-extract precursor has more clinical use, and cleanly attributing observed effects to Cortagen specifically rather than to the broader Cortexin/cortex-extract tradition has not been adequately done.
• 07Any cognitive endpoint at all — not one indexed study, in humans or animals, has tested Cortagen on a learning or memory task. The entire cognitive-enhancement framing rests on inference from the peptide being derived from cortex tissue, not on a measurement.
• 08The published negative results are unexplained — Cortagen did nothing in hypophysectomized and old birds where Epithalon worked (PMID 19432169) and nothing to thymocyte proliferation where Vilon and Epithalon were active (PMID 12420072). No follow-up has investigated why a near-identical sequence behaves so differently, which is the obvious test of the program's own one-peptide-one-tissue premise.
• 09Dose-response — every indexed experiment used a single concentration or a single injected dose. There is no dose-finding work of any kind, which means the capsule doses sold commercially have no empirical anchor.

Forms & Administration

Available as oral capsules. Treatment courses are typically 10-30 days.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Claims for cognitive enhancement, memory improvement, and neuroprotection exceed what the published Cortagen-specific evidence base can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Research-chemical injectable supply is not authorized for human use, and Russian dietary-complex products are not equivalent to approved Western medicines.

Timeline of Effects

Common Questions

Who Cortagen Is NOT For

Drug & Supplement Interactions

Documented clinical drug interactions for Cortagen are essentially absent; no formal interaction studies meeting Western standards have been published. Theoretical class concerns include concurrent use with psychotropic medications (antidepressants, antipsychotics, mood stabilizers), where Cortagen's proposed neuromodulatory mechanism could plausibly alter response, though the magnitude is unknown. Concurrent use with anticonvulsants is unstudied. Combination with other Khavinson bioregulators in nootropic stacks is common in forum culture but has not been formally evaluated for interaction safety. Patients on any psychiatric, neurological, or oncology-related medication should disclose Cortagen use to their prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions